Based on emerging clinical trial evidence, the 2022 ESMO Clinical Practice Guidelines [29] provided key recommendations of anti-PD-1/PD-L1 agents, including pembrolizumab, avelumab, durvalumab, dostarlimab, atezolizumab, and nivolumab, for the treatment of advanced or recurrent MSI-H or dMMR endometrial tumors, as well as those with high tumor mutational burden. The gene discussed is PDCD1; the disease is neoplasm.